Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1564353 | 0.75 | KMT2A (0.55) | LMNAKMT2ACYP2C19HTTNPSR1 | |
| SCHEMBL25849283 | 0.75 | LMNA (0.48) | LMNAKMT2ACYP2C19HTTNPSR1 | |
| SCHEMBL25853767 | 0.75 | LMNA (0.48) | LMNAKMT2ACYP2C19HTTNPSR1 | |
| SCHEMBL1574449 | 0.74 | LMNA (0.47) | LMNAKMT2ACYP2C19HTTNPSR1 | |
| SCHEMBL25849507 | 0.74 | LMNA (0.50) | LMNAKMT2ACYP2C19HTTNPSR1 | |
| SCHEMBL1574649 | 0.72 | LMNA (0.46) | LMNAKMT2ACYP2C19HTTNPSR1 | |
| SCHEMBL1576048 | 0.72 | LMNA (0.52) | LMNAKMT2ACYP2C19HTTNPSR1 | |
| SCHEMBL1574560 | 0.71 | LMNA (0.55) | LMNAKMT2ACYP2C19HTTNPSR1 | |
| SCHEMBL1574650 | 0.71 | LMNA (0.55) | LMNAKMT2ACYP2C19HTTNPSR1 | |
| SCHEMBL1574443 | 0.71 | LMNA (0.44) | LMNAKMT2ACYP2C19HTTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131430-A1 | PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-05-21 | — | — | US | disclosed |
| EP-1831215-A1 | PYRIDO[2,3-D]PYRIMIDINES AS ANTI-INFLAMATORY AGENTS | Ranbaxy Laboratories Limited (IN) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006056863-A1 | PYRIDO’2, 3-D!PYRIMIDINES AS ANTI-INFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131430-A1 | PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS | TLR1, TPMT, NOD1 | LMNA 4852/4885KMT2A 3310/4885CYP2C19 954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.